文献速递艾滋病与性传播感染结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

HIV/TB共感染儿童抗逆转录病毒与结核药物药代动力学系统综述

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该系统综述检索Embase和PubMed等数据库,纳入47项研究,评估HIV/TB共感染儿童中抗逆转录病毒药物与结核药物的药代动力学及药物相互作用。结果显示依非韦伦无需调整剂量但个体间变异大,整合酶抑制剂在年长儿中较有利,而小于3岁接受利福平方案儿童的抗逆转录病毒选择有限。

要点

  • 依非韦伦与一线抗结核方案联用无需调整剂量,但小于3岁儿童个体间药代动力学变异大。
  • 超级增效洛匹那韦/利托那韦(1:1)在利福平联用时可达到 adequate 洛匹那韦谷浓度。
  • 大于4周婴儿可用双倍剂量拉替拉韦与利福平联用,大于6岁儿童可用每日两次多替拉韦替代每日一次。

核心结论

  • 整合酶抑制剂在年长儿中似乎有利,但小于3岁接受利福平为基础抗结核治疗的儿童抗逆转录病毒选择有限。
  • HIV感染儿童中结核药物的药代动力学值得进一步研究。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索Embase和PubMed,并系统检索相关会议摘要集。
  • 共纳入47项符合标准的研究,所有研究均进行质量评估。

主要发现

  • 依非韦伦与一线抗结核治疗联用无需调整剂量,但个体间药代动力学变异大,尤其小于3岁儿童。
  • 超级增效洛匹那韦/利托那韦(比例1:1)在利福平联用期间可使洛匹那韦谷浓度达到 adequate 水平。
  • 大于4周龄儿童可双倍剂量拉替拉韦与利福平联用,大于6岁儿童可用每日两次多替拉韦替代每日一次。
  • 无论是否使用抗逆转录病毒治疗,HIV感染状态下乙胺丁醇和利福平等部分结核药物暴露降低。
  • HIV感染儿童中二线抗结核药物与抗逆转录病毒联用的药代动力学数据发表有限。

临床怎么用

  • 年长HIV/TB共感染儿童可优先考虑整合酶抑制剂为基础的抗逆转录病毒方案。
  • 小于3岁接受利福平方案儿童需关注依非韦伦个体间变异,并个体化评估抗逆转录病毒选择。
  • 利福平联用时洛匹那韦/利托那韦可采用1:1超级增效方案以维持洛匹那韦谷浓度。

局限性

  • 二线抗结核药物与抗逆转录病毒联用的儿童药代动力学数据有限。
  • 小于3岁接受利福平治疗儿童的抗逆转录病毒药代动力学证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Management of concomitant use of ART and TB drugs is difficult because of the many drug-drug interactions (DDIs) between the medications. This systematic review provides an overview of the current state of knowledge about the pharmacokinetics (PK) of ART and TB treatment in children with HIV/TB co-infection, and identifies knowledge gaps. METHODS: We searched Embase and PubMed, and systematically searched abstract books of relevant conferences, following PRISMA guidelines. Studies not reporting PK parameters, investigating medicines that are not available any longer or not including children with HIV/TB co-infection were excluded. All studies were assessed for quality. RESULTS: In total, 47 studies met the inclusion criteria. No dose adjustments are necessary for efavirenz during concomitant first-line TB treatment use, but intersubject PK variability was high, especially in children <3 years of age. Super-boosted lopinavir/ritonavir (ratio 1:1) resulted in adequate lopinavir trough concentrations during rifampicin co-administration. Double-dosed raltegravir can be given with rifampicin in children >4 weeks old as well as twice-daily dolutegravir (instead of once daily) in children older than 6 years. Exposure to some TB drugs (ethambutol and rifampicin) was reduced in the setting of HIV infection, regardless of ART use. Only limited PK data of second-line TB drugs with ART in children who are HIV infected have been published. CONCLUSIONS: Whereas integrase inhibitors seem favourable in older children, there are limited options for ART in young children (<3 years) receiving rifampicin-based TB therapy. The PK of TB drugs in HIV-infected children warrants further research.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Jacobs TG, Svensson EM, Musiime V, et al. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. J Antimicrob Chemother. 2020. PMID: 32785712. doi:10.1093/jac/dkaa328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。